• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
  • Featured Product
  • KD/KO Validated

PLAGL2 Polyklonaler Antikörper

PLAGL2 Polyklonal Antikörper für WB, Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus

Anwendung

WB, Indirect ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 11540-1-PBS

Synonyme

Filter:
  • Western Blot (WB) analysis of various lysates using PLAGL2 Polyclonal antibody (11540-1-AP)

    WB analysis using 11540-1-AP (same clone as 11540-1-PBS)

    Various lysates were subjected to SDS PAGE followed by western blot with 11540-1-AP (PLAGL2 antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 11540-1-PBS in a different storage buffer formulation.

Geprüfte Anwendungen

Produktinformation

11540-1-PBS bindet in WB, Indirect ELISA PLAGL2 und zeigt Reaktivität mit human, Maus

Getestete Reaktivität human, Maus
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen PLAGL2 fusion protein Ag2137
Vollständiger Name pleiomorphic adenoma gene-like 2
Berechnetes Molekulargewicht 496 aa, 55 kDa
Beobachtetes Molekulargewicht 50-55 kDa, 70 kDa
GenBank-ZugangsnummerBC023655
Gene symbol PLAGL2
Gene ID (NCBI) 5326
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

PLAGL2, also named KIAA0198, belongs to the krueppel C2H2-type zinc-finger protein family. It shows weak transcriptional activatory activity. PLAGL2, a proto-oncogene, is implicated in a variety of cancers including acute myeloid leukemia (AML), malignant glioma, colon cancer, and lung adenocarcinoma. PLAGL2 can function as a tumor suppressor by initiating cell cycle arrest and apoptosis. The calculated molecular weight of PLAGL2 is 55 kDa, but the SUMO1-modifIed form is 68 kDa (PMID: 30535429).